ÂÜÀòÂÒÂ×

Mark Nuttall, PhD, is the executive vice president of business development at Cambrian Biopharma. He was previously chief business officer for Kintai Therapeutics/Senda Biosciences, a Flagship Pioneering company, and Kymera Therapeutics (KYMR). Before moving to biotech, Dr. Nuttall held increasingly senior roles in business development functions at several large pharmaceutical companies. He was vice president and head of business development and licensing for core therapeutic franchises at Sanofi Genzyme: immunology, inflammation and multiple sclerosis; at Johnson & Johnson he led neuroscience business development and was responsible for leading a team that transformed the company's portfolio. Dr. Nuttall began his career in the healthcare industry in research and development at GlaxoSmithKline and AstraZeneca. He has a BSc in biochemistry from the University College of Wales in Cardiff, and a PhD in molecular and cell biology from the University of Aberdeen, Scotland.